• See how CrossBridge Bio is designing dual-payload ADCs to address key clinical questions on efficacy, durability, and safety

• Presenting preclinical evidence that demonstrates how proprietary dual-payload ADCs act synergistically to delay or prevent resistance in tumor models, including activity in resistant settings

• Revealing non-human primate data highlighting an improved therapeutic index and lack of overlapping toxicities compared to single-payload ADCs